资源类型：
WOS体系：
Pubmed体系：
收录情况：
◇ SCIE
文章类型：
单位：
[1]Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, Wuhan, Hubei, China.
华中科技大学同济医学院附属同济医院
ISSN：
关键词：
C type lectin
cancer cell glycolation
immune response
bacterial infection
tumor microenvironment
摘要：
C-type lectin receptors are a family of immune response receptors that can bind with a broad repertoire of ligands. It can function as innative immune receptors to surveillance bacteria, fungi, and virus invasions. The expressions of C-type lectin receptors (CLRs) are found in different types of tumors. But the role of C-type lectin receptors in cancer is not fully elucidated. And the underlying mechanisms of CLRs in carcinogenesis and tumor development remained unknown. It is known that CLRs bind to the glycosylated antigen on the cancer cells, regulating cancer cell invasion, migration, and metastasis. Meanwhile, the recognition of tumor glycans by antigen-presenting cells can stimulate antitumor immune response and induce immune tolerance. Also, some types of CLRs can be used as diagnostic markers for tumor cells, suggesting that C-type lectin can function as a new tumor therapeutic target and potential biomarkers. Given the therapeutic potential of CLRs in tumor treatments and the emerging roles of CLR in the tumor hallmarks, the multiple roles of CLRs in cancer were summarized in this review.Copyright © 2023 Li.
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类
|
3 区
医学
小类
|
3 区
肿瘤学
最新[2025]版：
大类
|
3 区
医学
小类
|
4 区
肿瘤学
影响因子：
最新[2023版]
最新五年平均
出版当年[2021版]
出版当年五年平均
出版前一年[2020版]
出版后一年[2022版]
第一作者：
第一作者单位：
[1]Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, Wuhan, Hubei, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Li Qiao.The multiple roles of C-type lectin receptors in cancer[J].FRONTIERS IN ONCOLOGY.2023,13:doi:10.3389/fonc.2023.1301473.
APA：
Li Qiao.(2023).The multiple roles of C-type lectin receptors in cancer.FRONTIERS IN ONCOLOGY,13,
MLA：
Li Qiao."The multiple roles of C-type lectin receptors in cancer".FRONTIERS IN ONCOLOGY 13.(2023)
